Alnylam Pharma (ALNY) Misses Q4 EPS by 11c
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $288.18 +0.62%
Revenue Growth %: +70.6%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
CRWS, MEI, PODC, More
Revenue Growth %: +70.6%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
CRWS, MEI, PODC, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.07), $0.11 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $7.6 million versus the consensus estimate of $9.1 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- MSCI acquires First Street for $120M to expand climate risk data
- Goldman Sachs Assumes Klaviyo Inc (KVYO) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
